Scotland’s health technology assessment body, the Scottish Medicines Consortium, has accepted Regeneron Pharmaceuticals Inc. / Sanofi’s conditionally approved skin cancer treatment, Libtayo (cemiplimab), for interim funding on the Scottish National Health Service. Other treatments that recently got the thumbs up from the SMC include Pierre Fabre Group’s Braftovi (encorafenib), also for skin cancer, and Takeda Pharmaceutical Co. Ltd.’s Revestive (teduglutide) for short bowel syndrome.
Scotland Recommends Interim Funding For Regeneron/Sanofi’s Libtayo
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.

More from Europe
More from Geography
Pink Sheet reporter and editors discuss FDA Commissioner Martin Makary’s decision to have one of his assistants lead negotiations for Novavax’s delayed COVID-19 vaccine review, as well as some recent missed review deadlines, which may be the result of recent FDA cuts.
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.